


Surgeons Play a Pivotal Role in the Patient Journey for Resectable NSCLC¹



MDT, multidisciplinary team; NSCLC, non-small cell lung cancer.


1. Al Zaidi M, et al. *Transl Lung Cancer Res.* 2020;9(4):1680-1689. 2. National Cancer Institute. Accessed April 28, 2022. <https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq>. 3. Popat S, et al. *Oncologist.* 2021;26(2):e306-e315. 4. Zuccato JA, Ellis PM. *Curr Oncol.* 2012;19(6):e422-e427. 5. Urquhart R, et al. *CMAJ Open.* 2016;4(1):E7-E12. 6. Postmus PE, et al; ESMO Guidelines Committee. *Ann Oncol.* 2017;28(suppl 4):iv1-iv21.





Biomarker Testing in the Resectable Setting May Be Performed Using Diagnostic Biopsy Tissue or Resected Tissue

Example of a Patient Journey for Resectable NSCLC¹



NSCLC, non-small cell lung cancer.

1. National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version. <https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq>. Accessed April 28, 2022. 2. Coley SM, et al. *Cancer Cytopathol.* 2015;123(5):318-326. 3. Schmid-Bindert G, et al. *PLoS One.* 2013;8(10):e779848. 4. Lim C, et al. *Curr Oncol.* 2017;24(2):103-110. 5. Aisner D, Marshall CB. *Am J Clin Pathol.* 2012;138(3):332-346. 6. Owen D, Chaff J. *J Thorac Dis.* 2018;10(suppl 3):S404-S411. 7. Salazar MC, et al. *JAMA Oncol.* 2017;3(5):610-619.

